The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress

Cardiovascular Drugs and Therapy

Volumn 21, Issue 2, 2007, Pages 91-97

  Mulder, Douwe J ^a   Van Haelst, Paul L ^a   Wobbes, Martgriet H ^a   Gans, Rijk O ^a   Zijlstra, Felix ^a   May, Johan F ^a   Smit, Andries J ^a   Tervaert, Jan Willem Cohen ^b   Van Doormaal, Jasper J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Arteriosclerosis; Atorvastatin; C reactive protein; Hydroxymethylglutaryl CoA reductase inhibitors; Inflammation; Neopterin; Oxidized low density lipoprotein; Simvastatin; Soluble cellular adhesion molecules; Von Willebrand Factor

Indexed keywords

ANTIBODY; ANTILIPEMIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEOPTERIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NEOPTERIN; OXIDATIVE STRESS; PYRROLES; SIMVASTATIN; VON WILLEBRAND FACTOR;

EID: 34249706343     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6010-x     Document Type: Article

References (30)

1. Cannon CP, Braunwald E, Mccabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
2. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
3. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.
4. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
7. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47:C19-31.
8. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction?: a meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62.
9. Kwak BR, Mach F. Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001;21:1256-8.
10. Damoiseaux J, Jeyasekharan AD, Theunissen R, Tervaert JW. Cross-reactivity of IgM and IgG anticardiolipin antibodies with oxidized-low density lipoproteins. Ann N Y Acad Sci 2005;1050:163-9.
11. Stegeman CA, Tervaert JW, Huitema MG, de Jong PE, Kallenberg CG. Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during followup. Arthritis Rheum 1994;37:1228-35.
12. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. J Am Med Assoc 2005;294:2437-45.
13. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
14. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne C, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65.
15. Nissen SE. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
16. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002;165:361-6.
17. Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 2004;27:199-203.
18. Kinlay S, Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002;89:1205-7.
19. Trip MD, van Wissen S, Smilde TJ, Hutten BA, Stalenhoef AF, Kastelein JJ. Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. Am J Cardiol 2003;91:604-6.
20. Van de Ree MA, De Maat MP, Kluft C, Meinders AE, Princen HM, Huisman MV. Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. J Thromb Haemost 2003;1:1753-7.
21. Tamura A, Watanabe T, Nasu M. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circulation 2003;67:816-20.
22. Van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 2004;52:177-84.
23. Ridker PM. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
24. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003;139:670-82.
25. Jilma B, Joukhadar C, Derhaschnig U, Rassoul F, Richter V, Wolzt M, et al. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia. Clin Sci (Lond) 2003;104:189-93.
26. Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond) 2004;106:215-7.
27. Ogushi F, Tani K, Endo T, Tada H, Tetsuya K, Asano T, et al. Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis. J Med Invest 2001;48:181-9.
28. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow G, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
29. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:1814-21.
30. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.